Nature 612 , 720724 (2022)
In addition to weight loss, Wegovy is FDA-approved to reduce the risk of major adverse cardiovascular events like heart attack and stroke in obese or overweight adults with heart disease
These reports prompted regulatory agencies in multiple countries to investigate whether a causal relationship exists between these medications and suicidal thoughts or behaviors
Based on these results, in March 2024, the FDA approved a new indication for Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight
What the evidence suggests: dermatological observations have noted skin-brightening effects, particularly in hyperpigmentation, melasma, and post-inflammatory darkening